SecBot SecBot

ABEO

ABEONA THERAPEUTICS INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000318306 Biotech & Drug Discovery
$2.60 +0.18 (+7.44%)
Nov 16 4:00 PM ET · prev $2.42
Market cap
$130.9M
Micro cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$15.50
+496% · range $7.50–21.00
Next earnings
Nov 16
today · EPS est. −$0.17
1 year
−42.4%
from $4.51 · Nov 17
30 days
−41.0%
from $4.41
52-week range
$2.29–7.46
−65% from high · low Nov 12
Avg volume 20D
2.21M
Nov 9 spike 13.57M
Short interest
16.88M
≈29.5% of shares · −1.9%
Days to cover
21.7
at average volume
Insider net
🔒 Subscribers only
New fund stakes
0
Q3 2026 13F · 1 exit
SecBot read MIXED 11 reports · 90 days
Balance 2 bearish · 2 bullish · 1 mixed · 6 neutral oldest → newest, height = score
Avg score ·High conf. 7/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersLOCKED

    1 open-market trade filed or updated in the last 24 hours. 🔒 Subscribers only.

  • InstitutionsMIXED

    Q3 2026: 15 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.110 → −$0.170 over 90 days.

  • Short sellersSTEADY

    Short interest −1.9% to 16.88M shares. 21.7 days to cover, ≈29.5% of shares.

  • TrendDOWNTREND

    44% below its 50-day average. New closing low $2.29 on Nov 12.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 29.

Who's buying

13F· Q3 2026
0
new positions
1
exit
FundMoveSharesValue
CITIGROUP INCADD874,649$4.6M
BARCLAYS PLCADD602,576$3.2M
PANAGORA ASSET MANAGEMENT INCADD527,147$2.8M
DIMENSIONAL FUND ADVISORS LPDOUBLED194,201$1.0M
AMERICAN CENTURY COMPANIES INCADD74,056$388.8K
BNP PARIBAS FINANCIAL MARKETSDOUBLED69,924$367.1K
FMR LLCTRIM41,457$217.6K
Creative PlanningADD28,746$150.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy5Buy7Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +496%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 12, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 9, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
Sep 18, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
Sep 17, 2026Roth Capital
INITIATE
INITIATEBuy
Aug 14, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
May 28, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
🔒 Subscribers only
35 transactions
DateInsiderTypeValue
Nov 13, 2026🔒 Fresh data, subscribers only
Nov 13, 2026
BUY
Sep 29, 2026
Vasanthavada Madhav
Chief Commercial Officer
Sep 29, 2026
SELL$25.3K
Sep 29, 2026
O'Malley Brendan M.
SVP, Chief Legal Officer
Sep 29, 2026
SELL$34.7K
Sep 29, 2026
Vazzano Joseph Walter
Chief Financial Officer
Sep 29, 2026
SELL$47.4K
Sep 29, 2026
Seshadri Vishwas
Chief Executive Officer
Sep 29, 2026
SELL$101.1K
Sep 1, 2026
Alvino Mark
Director
Sep 1, 2026
SELL$88.0K
Jul 21, 2026
Vazzano Joseph Walter
Chief Financial Officer
Jul 21, 2026
SELL$9.7K
Jul 9, 2026
O'Malley Brendan M.
SVP, Chief Legal Officer
Jul 9, 2026
SELL$83.9K

Earnings setup

Estimates
Nov 16
reports today
−$0.17
EPS estimate, this quarter
−55%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.17-$0.25–-$0.05-27.5%$12.6M
Next Q-$0.22-$0.24–-$0.16-72.5%$12.9M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
16,879,896
shares short
-1.9%
vs prior settlement
21.7
days to cover
≈29.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Earnings calendar
ABEO Q3 2026 Earnings Scheduled · 2026-11-16
Nov 13, 2026 SEC
Funicular Funds, LP filed an amended Schedule 13G disclosing a 7.5% passive stake in Abeona Therapeutics as of…
SC 13G/A · Impact 3/10
Nov 13, 2026 Insider
🔒 Fresh data, subscribers only
Nov 12, 2026 SEC
Daniel Kaufman filed an amended Schedule 13G disclosing a 7.3% passive stake in Abeona Therapeutics as of September…
SC 13G/A · Impact 3/10
Nov 9, 2026 Press
Abeona Therapeutics acquires ABO-801 (formerly APT-1011), a Phase 3-ready oral therapy for eosinophilic esophagitis…
Impact 6/10
Sep 30, 2026 Inst.
CITIGROUP INC · ADD
874,649 shares ($4.6M)
Sep 30, 2026 Inst.
BARCLAYS PLC · ADD
602,576 shares ($3.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent
Nov 16, 2026
Earnings date
ABEO Q3 2026 Earnings Scheduled · 2026-11-16
Nov 10, 2026
Press release
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will…
Nov 9, 2026
Earnings
Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2
Nov 9, 2026
M&A
Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement
- Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations
Nov 2, 2026
Press release
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new…

SecBot reports

24 filings · 5 press releases · 2 bullish · 4 bearish · 1 mixed · 17 neutral
All ABEO filing & press-release reports (29)